41 completed, 4 unknown, 1 not yet recruiting, 1 recruiting. 49 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 49 | Completed 41, Unknown 4, Not yet recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 8 | Completed 6, Unknown 1, Withdrawn 1 |
Follow Risperidone: new trials by email Literature Review of Risperidone trials Research Report on Risperidone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Shortened LSD Intervention for Major Depressive Disorder LSD, Risperidone - Major Depression Moderate, Major Depression Severe | Phase 1 | Not yet recruiting | Johns Hopkins University | 10 | 2026-12-01 | 2026-11-03 |
| Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects Psilocybin (Usona Institute), Risperidone 1 MG, MRI - Depression - Major Depressive Disorder, Anhedonia | Phase 1 | Recruiting | Medical University of Vienna | 85 | 2025-11-01 | 2026-03-24 |
| Result of tDCS in ASD Children With Comorbidities Like PANDAS, Rare Genetic Diseases or Autoimmune Disorders tDCS or Transcranial Direct Current Stimulation, Risperidone, Sham tDCS - Attention, Visual Perceptual Weakness | Phase 1 / Phase 2 | Completed | Spanish Foundation for Neurometrics Development | 180 | 2024-04-01 | 2026-09-10 |
| KF2022#3-trial: Effect of Tea and Cola Beverage on Absorption of Risperidone Oral Solution Risperidone oral solution - Psychosis, Food-drug Interaction | Phase 1 | Completed | Helsinki University Central Hospital | 12 | 2023-12-08 | 2024-12-05 |
| Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia Oral risperidone; QUAR F1/2, Dose 1 - Gluteal, Oral risperidone; QUAR F1/2, Dose 2 - Gluteal, Oral risperidone; QUAR F1/2, Dose 3 - Gluteal - Schizophrenia | Phase 1 | Completed | Rovi Pharmaceuticals Laboratories | 58 | 2023-09-26 | 2025-09-08 |
| A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole) - Schizophrenia | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 19 | 2022-11-15 | 2024-06-26 |
| A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole) - Schizophrenia | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 31 | 2022-06-13 | 2024-06-26 |
| Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant Risperidone - Schizophrenia | Phase 1 / Phase 2 | Completed | Delpor, Inc. | 34 | 2021-04-01 | 2024-12-27 |
| Comparative Bioavailability of Risperidone. Risperidone ISM® 100 mg, Risperdal 4mg Tablet - Schizophrenia | Phase 1 | Completed | Rovi Pharmaceuticals Laboratories | 80 | 2021-03-09 | 2022-01-05 |
| Electrical Brain Stimulation and Pharmacological Treatments in Autism Spectrum Disorder RisperiDONE 1 MG/ML, transcranial direct current stimulation, Placebo - Autism Spectrum Disorder | Phase 1 | Completed | The National Brain Mapping Laboratory (NBML) | 45 | 2020-08-15 | 2023-11-07 |
| Symptomatic Therapy for Patients With Huntington's Disease Haloperidol 2Mg Tab, Risperidone 1Mg Tab, Zoloft 50Mg Tablet - Huntington Disease | Phase 1 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 60 | 2020-03-12 | 2021-04-02 |
| PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia RBP-7000 - Schizophrenia | Phase 1 | Completed | Indivior Inc. | 44 | 2016-02-01 | 2017-01-31 |
| Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone Aripiprazole, Olanzapine, Paliperidone - Immunoassay, Antipsychotic | Phase 1 | Completed | Janssen Research & Development, LLC | 81 | 2015-11-09 | 2025-08-15 |
| Nicotinic Receptors and Schizophrenia Risperidone plus Placebo, Risperidone plus DMXB-A - Schizophrenia | Phase 1 / Phase 2 | Withdrawn | VA Office of Research and Development | 2015-08-01 | 2017-05-30 | |
| Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia ZX003 (Risperidone-SABER®), Risperdal Consta, Oral Risperidone - Schizophrenia, Schizoaffective Disorder | Phase 1 | Completed | Zogenix, Inc. | 60 | 2015-02-01 | 2022-10-31 |
| Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation - Psychotic Disorders, Schizophrenia | Phase 1 | Completed | Janssen Research & Development, LLC | 305 | 2014-02-01 | 2015-10-29 |
| A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone Placebo, RO5545965, risperidone - Schizophrenia | Phase 1 | Completed | Hoffmann-La Roche | 32 | 2014-01-01 | 2016-11-02 |
| Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study Cannabidiol CR, Cannabidiol, Amisulpride - Schizophrenia | Phase 1 | Completed | Central Institute of Mental Health, Mannheim | 74 | 2013-01-01 | 2018-03-08 |
| The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment Risperidone, Olanzapine, Quetiapine - Schizophrenia | Phase 1 / Phase 2 | Unknown | Shanxi Medical University | 200 | 2013-01-01 | 2016-01-08 |
| A Study of the Combination of Multiple Doses of RO5285119 With a Single Dose of Risperidone in Healthy Volunteers RO5285119, RO5285119 placebo, risperidone - Healthy Volunteer | Phase 1 | Completed | Hoffmann-La Roche | 24 | 2012-11-01 | 2016-11-02 |
Showing 20 of 49. Sign in to see all of them.
Schizophrenia (21) · Psychotic Disorders (5) · Depression (3) · Autistic Disorder (2) · Bipolar Disorder (2) · Child Development Disorders, Pervasive (2) · Anhedonia (1) · Autism Spectrum Disorder (1) · Cocaine-Related Disorders (1) · Depressive Disorder (1) · Depressive Disorder, Major (1) · Depressive Disorder, Treatment-Resistant (1) · Dyskinesia, Drug-Induced (1) · Fasting (1) · Huntington Disease (1)
Dr. Reddy's Laboratories Limited (4) · Janssen Research & Development, LLC (3) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (3) · Children's Hospital Medical Center, Cincinnati (2) · GlaxoSmithKline (2) · Hoffmann-La Roche (2) · IPCA Laboratories Ltd. (2) · Indivior Inc. (2) · Otsuka Pharmaceutical Development & Commercialization, Inc. (2) · Rovi Pharmaceuticals Laboratories (2) · Teva Pharmaceuticals USA (2) · Torrent Pharmaceuticals Limited (2) · Calo Psychiatric Center (1) · Central Institute of Mental Health, Mannheim (1) · Corcept Therapeutics (1)
United States (20) · India (5) · Spain (4) · Belgium (3) · Canada (3) · China (2) · Germany (2) · Argentina (1) · Austria (1) · Brazil (1) · Bulgaria (1) · Finland (1) · France (1) · Iran (1) · Jordan (1)
Benoit Girard, MD (2) · Dr. Tarang Shah, M.D. (2) · Geatano Morelli, M.D (2) · Alexander Vinks, Pharm.D., Ph.D. (1) · Amalia Lafuente Flo, Pharmacology professor (1) · Anthony Levitt, MD (1) · Barbara O Rothbaum, PHD (1) · Coleman Gross, MD (1) · David Walling, PhD (1) · Dilip V. Jeste, MD (1)
PMID 18278987, PMID 22513041, PMID 24519692, PMID 25468234, PMID 27173384, PMID 29625151, PMID 30509308, PMID 33578648, PMID 33658971, PMID 33823927, PMID 35734582, PMID 37445385
2008 (1), 2009 (1), R01MH059101 (1), R44MH094036 (1)